|
1
|
Lapuente JP, Gómez G, Marco-Brualla J, Fernández P, Desportes P, Sanz J, García-Gil M, Bermejo F, San Martín JV, Algaba A, De Gregorio JC, Lapuente D, De Gregorio A, Lapuente B, Gómez S, Andrés MDLV, Anel A. Evaluation in a Cytokine Storm Model in Vivo of the Safety and Efficacy of Intravenous Administration of PRS CK STORM (Standardized Conditioned Medium Obtained by Coculture of Monocytes and Mesenchymal Stromal Cells). Biomedicines 2022; 10:biomedicines10051094. [PMID: 35625831 PMCID: PMC9138962 DOI: 10.3390/biomedicines10051094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2022] [Revised: 05/02/2022] [Accepted: 05/05/2022] [Indexed: 11/16/2022] Open
Abstract
Our research group has been developing a series of biological drugs produced by coculture techniques with M2-polarized macrophages with different primary tissue cells and/or mesenchymal stromal cells (MSC), generally from fat, to produce anti-inflammatory and anti-fibrotic effects, avoiding the overexpression of pro-inflammatory cytokines by the innate immune system at a given time. One of these products is the drug PRS CK STORM, a medium conditioned by allogenic M2-polarized macrophages, from coculture, with those macrophages M2 with MSC from fat, whose composition, in vitro safety, and efficacy we studied. In the present work, we publish the results obtained in terms of safety (pharmacodynamics and pharmacokinetics) and efficacy of the intravenous application of this biological drug in a murine model of cytokine storm associated with severe infectious processes, including those associated with COVID-19. The results demonstrate the safety and high efficacy of PRS CK STORM as an intravenous drug to prevent and treat the cytokine storm associated with infectious processes, including COVID-19.
Collapse
Affiliation(s)
- Juan Pedro Lapuente
- R4T Molecular and Cell Biology Research Laboratories, Fuenlabrada Hospital, 28942 Madrid, Spain; (G.G.); (P.F.); (J.C.D.G.); (D.L.); (A.D.G.); (B.L.); (S.G.); (M.d.l.V.A.)
- Correspondence: (J.P.L.); (A.A.)
| | - Gonzalo Gómez
- R4T Molecular and Cell Biology Research Laboratories, Fuenlabrada Hospital, 28942 Madrid, Spain; (G.G.); (P.F.); (J.C.D.G.); (D.L.); (A.D.G.); (B.L.); (S.G.); (M.d.l.V.A.)
| | - Joaquín Marco-Brualla
- Group Immunity, Cancer and Stem Cells, Faculty of Sciences, University of Zaragoza, 50009 Zaragoza, Spain;
| | - Pablo Fernández
- R4T Molecular and Cell Biology Research Laboratories, Fuenlabrada Hospital, 28942 Madrid, Spain; (G.G.); (P.F.); (J.C.D.G.); (D.L.); (A.D.G.); (B.L.); (S.G.); (M.d.l.V.A.)
| | - Paula Desportes
- GMP Facility, Peaches Biotech, 28050 Madrid, Spain; (P.D.); (J.S.)
| | - Jara Sanz
- GMP Facility, Peaches Biotech, 28050 Madrid, Spain; (P.D.); (J.S.)
| | | | - Fernando Bermejo
- Digestive Department, Fuenlabrada Hospital, 28942 Madrid, Spain;
- Medicine Department, University Rey Juan Carlos, 28942 Madrid, Spain
| | | | - Alicia Algaba
- Clinical Assay Department, Fuelabrada Hospital, 28942 Madrid, Spain;
| | - Juan Carlos De Gregorio
- R4T Molecular and Cell Biology Research Laboratories, Fuenlabrada Hospital, 28942 Madrid, Spain; (G.G.); (P.F.); (J.C.D.G.); (D.L.); (A.D.G.); (B.L.); (S.G.); (M.d.l.V.A.)
| | - Daniel Lapuente
- R4T Molecular and Cell Biology Research Laboratories, Fuenlabrada Hospital, 28942 Madrid, Spain; (G.G.); (P.F.); (J.C.D.G.); (D.L.); (A.D.G.); (B.L.); (S.G.); (M.d.l.V.A.)
| | - Almudena De Gregorio
- R4T Molecular and Cell Biology Research Laboratories, Fuenlabrada Hospital, 28942 Madrid, Spain; (G.G.); (P.F.); (J.C.D.G.); (D.L.); (A.D.G.); (B.L.); (S.G.); (M.d.l.V.A.)
| | - Belén Lapuente
- R4T Molecular and Cell Biology Research Laboratories, Fuenlabrada Hospital, 28942 Madrid, Spain; (G.G.); (P.F.); (J.C.D.G.); (D.L.); (A.D.G.); (B.L.); (S.G.); (M.d.l.V.A.)
| | - Sergio Gómez
- R4T Molecular and Cell Biology Research Laboratories, Fuenlabrada Hospital, 28942 Madrid, Spain; (G.G.); (P.F.); (J.C.D.G.); (D.L.); (A.D.G.); (B.L.); (S.G.); (M.d.l.V.A.)
| | - María de las Viñas Andrés
- R4T Molecular and Cell Biology Research Laboratories, Fuenlabrada Hospital, 28942 Madrid, Spain; (G.G.); (P.F.); (J.C.D.G.); (D.L.); (A.D.G.); (B.L.); (S.G.); (M.d.l.V.A.)
| | - Alberto Anel
- Group Immunity, Cancer and Stem Cells, Faculty of Sciences, University of Zaragoza, 50009 Zaragoza, Spain;
- Correspondence: (J.P.L.); (A.A.)
| |
Collapse
|
|
2
|
Cytokine Profile and Anti-Inflammatory Activity of a Standardized Conditioned Medium Obtained by Coculture of Monocytes and Mesenchymal Stromal Cells (PRS CK STORM). Biomolecules 2022; 12:biom12040534. [PMID: 35454123 PMCID: PMC9029939 DOI: 10.3390/biom12040534] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Revised: 03/27/2022] [Accepted: 03/29/2022] [Indexed: 02/01/2023] Open
Abstract
Intercellular communication between monocytes/macrophages and cells involved in tissue regeneration, such as mesenchymal stromal cells (MSCs) and primary tissue cells, is essential for tissue regeneration and recovery of homeostasis. Typically, in the final phase of the inflammation-resolving process, this intercellular communication drives an anti-inflammatory immunomodulatory response. To obtain a safe and effective treatment to counteract the cytokine storm associated with a disproportionate immune response to severe infections, including that associated with COVID-19, by means of naturally balanced immunomodulation, our group has standardized the production under GMP-like conditions of a secretome by coculture of macrophages and MSCs. To characterize this proteome, we determined the expression of molecules related to cellular immune response and tissue regeneration, as well as its possible toxicity and anti-inflammatory potency. The results show a specific molecular pattern of interaction between the two cell types studied, with an anti-inflammatory and regenerative profile. In addition, the secretome is not toxic by itself on human PBMC or on THP-1 monocytes and prevents lipopolysaccharide (LPS)-induced growth effects on those cell types. Finally, PRS CK STORM prevents LPS-induced TNF-A and IL-1Β secretion from PBMC and from THP-1 cells at the same level as hydrocortisone, demonstrating its anti-inflammatory potency.
Collapse
|
|
4
|
Xu W, Meng K, Wu H, Miura T, Suzuki S, Chiyotanda M, Tanaka S, Sugiyama K, Kawashima H, Hirano T. Vitamin K 2 immunosuppressive effect on pediatric patients with atopic dermatitis. Pediatr Int 2019; 61:1188-1195. [PMID: 31560147 DOI: 10.1111/ped.14014] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2019] [Revised: 07/25/2019] [Accepted: 09/24/2019] [Indexed: 12/21/2022]
Abstract
BACKGROUND Over 20 kinds of steroids, tacrolimus ointments, and cyclosporine capsules are usually recommended for the treatment of atopic dermatitis (AD), depending on the symptoms of patients. However, several side effects sometimes occur with the extensive use of these agents for the treatment of pediatric AD patients. The purpose of this study was to explore whether vitamin K2 could be a new immunosuppressive candidate for pediatric patients with AD. METHODS The immunosuppressive efficacy of vitamin K2 was evaluated through a cell-culture procedure using mitogen-activated peripheral blood mononuclear cells (PBMCs) obtained from pediatric AD patients. RESULTS The mean (SD) IC50 value of vitamin K2 for the proliferation of concanavalin A-activated PBMCs was 15.37 (30.05) μmol/L, while the value for tacrolimus was 0.10 (0.28) ng/mL (0.12 (0.35) nmol/L). There was a significant correlation between the IC50 values for vitamin K2 and those for tacrolimus (P = 0.0001, r = 0.8871). However, there was no significant correlation between the IC50 values of vitamin K2 and those of cyclosporine A or methylprednisolone. A significant correlation between the IC50 values of vitamin K2 or tacrolimus and blood eosinophil counts (P = 0.0099, r = 0.7086 and P = 0.0032, r = 0.7722, respectively) was observed. CONCLUSION Vitamin K2 -inhibited T-cell mitogen stimulated proliferation of PBMCs from pediatric AD patients in a dose-dependent manner. The PBMCs from pediatric AD patients were more sensitive to the immunosuppressive efficacy of vitamin K2 than the PBMCs from healthy subjects. The individual immunosuppressive pharmacological efficacy of vitamin K2 and of tacrolimus could be inferred from the blood eosinophil count of pediatric AD patients.
Collapse
Affiliation(s)
- Wencheng Xu
- Department of Pharmacy, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, China.,Institute of Traditional Chinese Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, China
| | - Kehan Meng
- Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan
| | - Hongguang Wu
- Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan
| | - Taro Miura
- Department of Pediatrics and Adolescent Medicine, Tokyo Medical University Hospital, Shinjuku-ku, Tokyo, Japan
| | - Shunsuke Suzuki
- Department of Pediatrics, Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan
| | - Masako Chiyotanda
- Department of Pediatrics and Adolescent Medicine, Tokyo Medical University Hospital, Shinjuku-ku, Tokyo, Japan
| | - Sachiko Tanaka
- Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan
| | - Kentaro Sugiyama
- Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan
| | - Hisashi Kawashima
- Department of Pediatrics and Adolescent Medicine, Tokyo Medical University Hospital, Shinjuku-ku, Tokyo, Japan
| | - Toshihiko Hirano
- Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan
| |
Collapse
|